






Figure 4A
























Mass/Charge
























Mass/Charge











1st dimension: Isoelectric focusing



2nd dimension: SDS PAGE










Figure 17


Fig. 18














Normalized marker peak area (marker/internal std):


Control 0.0
Disease 0.61
Drug treated 0.05


Retentate MapTM of Human Urine SELDI ProteinChipTM Array
















Binding in the presence of excess free receptor (---)


TGFB (100 ng/ml 2.5xconditioned medium)

Fig. 27B









Molecular weight





Fig. 33A

Intensity

Fig. 33B



Mass/charge